Bristol Myers scores FDA priority review in high-stakes expansion bid for CAR-T drug Breyanzi
The FDA has accepted Bristol Myers Squibb's application for Breyanzi as a second-line treatment for relapsed or refractory large B-cell lymphoma. The regulator has assigned it priority review with a decision deadline of June 24.
Source: fiercepharma.com